IDEA² October 2021

Liposphere – Enabling smooth articulation of joints





PRIVATE & CONFIDENTIAL © by Liposphere Ltd.



Pinpointing the problem Osteoarthritis

()))

// Degenerative Joint Disease

> Progressive breakdown/loss of cartilage> Pain and limitation of active lifestyle

// Current treatment solutions:
partially beneficial and time-limited



Over 300M people globally suffer from Osteoarthritis.









AqueousJoint Our Solution

()3



Mode of Action: Hydration Lubrication Mechanism⁴



- "A revolutionary, water-based, biocompatible
- knee joint articulation compound to restore cartilages' natural mechanical properties."



Long shelf stability Scalable for mass production **Encapsulation potential**











Liposphere's orthopedic product AqueousJoint

()4

...forms a hydrated, protective coating on cartilage to treat Osteoarthritis as a local knee injectable.

Anticipated patient benefits

Reduction of pain by protecting cartilage \checkmark

Delaying surgery and improve dosing schedule.

Resume normal activities.



Liposphere's orthopedic product Why **Aqueous** Joint?



Why and how should a lubricant work?

Osteoarthritis and Cartilage 21 (2013) 1660-1667

Osteoarthritis and Cartilage

() 5



Sustained clinical and structural benefit after joint distraction in the treatment of severe knee osteoarthritis



K. Wiegant †‡, P.M. van Roermund ‡, F. Intema †, S. Cotofana §, F. Eckstein §, S.C. Mastbergen †, F.P.J.G. Lafeber †*



It is hypothesized that temporary joint ... distraction prevents mechanical stress on the cartilage, prevents further wear and tear and allows tissue repair to begin."

Boundary lubricants could potentially initiate tissue repair



Retention time study in mice



T = 72 hours post-injection.





Efficacy study in mice*

Intra-articular injection of phospholipid-based lubricant reduces shear-responsive inflammatory genes in the superficial layer of cartilage post joint destabilization.

* Collaboration Prof Jacob Klein Weizmann Institute/Prof. Tonia Vincent Oxford University



















Osteoarthritis Current solutions

06



We focus on Stage 2 treatment aiming to delay Total Knee Replacement.



Stage II – local injectables

Corticosteroids	Hyaluronic acid-based
Drug	Visco-supplemen t
anti-inflammatory, pain relief	<pre>// delayed pain relief effect,</pre>
cts rapidly	but up to 6 months
short-term effect	// controversial clinical benefit
ide effect: cartilage damage	// less effective in older adults
estricted to 3-5x per year	and severe cases

.



Global **Osteoarthritis Therapeutics Market**







Customer target segment Global HA knee injectable market

Global HA Injectable market \$18.6Bn

7Bn

Global OA Therapeutics market \$11Bn

Key players: Sanofi, Ferring, Fidia, Seikagaku, Anika Therapeutics, Zimmer Biomet, Fidia...





A comparison Why Aqueous Joint?

Protection against wear and tear

08

Mode of Action

Retention time









Key metrics Accomplished Milestones

Preclinical/clinical milestones

- ✓ Tech transfer to own facility
- ✓ ISO 13485:2016 certification
- ✓ Upscaled in-house manufacturing
- ✓ Retention time study in-vivo
- Preclinical biocompatibility
- ✓ In process of 2 in-vivo efficacy studies
- ✓ Submission ethical application FIH study



Strategic and business milestones



✓ Raised seed-funding (USD 7.3M):

private and Israel Innovation Authority

- Finalist MassChallenge accelerator, Spinoff Prize \checkmark
- Participant MIT IDEA² program \checkmark
- Winner AO development incubator \checkmark
- In discussions with potential strategic partners \checkmark



An outlook Next steps *AqueousJoint*

Partnership or New Financing

FDA Pre-Sub submission Q3 2022

10

First-In-Human study (Israel) Q4 2021

Scale Up GMP Manufacturing Q3/4 2021



Who we are Liposphere's IDEA² Team



PhD in Chemistry Weizmann Institute

" We founded Liposphere as a spin-off from the Weizmann Institute of Science (Israel) in 2019 after having worked several years together in an academic setting."



11

Scientific: Prof Jacob Klein (Weizmann); Clinical: Dr Gabi Agar, Asaf Harofeh Hospital, Business: Yael Baratz (Pearl Cohen Baratz), Keren Haruvi-Snir, President Sandoz North America





Sabrina Jahn Co-Founder, Business Development

PhD in Physics University of Cambridge

What happened since June Update

// Key accomplishments

12

- *Clinical:* Submission FIH trial request
- Developmental progress: Large animal safety, Ex-vivo on cartilage and wear efficacy, analytics Filing *patent* protecting *product manufacturing method*
- *Company structure:* hired 4 new employees, IAA granted 3rd year of funding
- Business: Winner of AO incubator program

// Key communication: what did we learn?

- Orthopaedic clinicians: willingness to evaluate AqueousJoint, retention time as crucial measure Potential investors: understanding interest of investing







Liposphere Ltd. A'arava 1 6th Floor Givat Shmuel 5400804 Israel

Office +972 (0) 732-113-227 contact@lipo-sphere.com www.lipo-sphere.com





nature research awards









AqueousJoint Impact Statement

For Osteoarthritis patients with chronic knee pain, it's a challenge to maintain an active, pain-free life-style. Today, their best options are regular local injections of hyaluronic acid or corticosteroids which, because of poor long-term effectiveness yields continuing pain, frequent visits to the doctor with painful injections. Thus, there is a need to extend the effectivity of the injectables to treat OA patients which, if solved, will improve the quality of life by reducing pain enabling normal activities.

Solving this need can be achieved by the use of our long lasting, patented joint articulation compound AqueousJoint that will restore the natural lubrication properties of cartilage and will be demonstrated by the reduction of knee pain.





AqueousJoint Todays workflow + AqueousJoint



A2





AqueousJoint References

1. Osteoarthritis Therapeutics Market - Global Forecast to 2025 | Markets and Markets 2. Hyaluronic Acid Market Size | Industry Analysis Report, 2020-2027 (grandviewresearch.com) 3. Hyaluronic Acid Injection Market Ravishing USD 18.6 Bn by 2028 Corneal (Allergan), Galdermal (Q-Med), LG Life Science, **Bohus BioTech, IMEIK,**

4. Raviv U, Laurat P, Klein J. Fluidity of water confined to subnanometre films. Nature. 2001;413(6851):51-54.

Goldberg R, Schroeder A, Silbert G, Turjeman K, Barenholz Y, Klein J. Boundary lubricants with exceptionally low friction coefficients based on 2D close-packed phosphatidylcholine liposomes. Adv Mater. 2011;23(31):3517-3521.

Jahn S, Seror J, Klein J. Lubrication of Articular Cartilage. Annual review of biomedical engineering. 2016;18:235-258.



AqueousJoint technology Liposphere's joint articulation compound

Efficient at high-loads **Reduces wear and friction Provides superior lubrication** anticipated to be classified as medical device

A4

Formulations hold water in the most efficient way.



Lipid-based sphere

Zwitterionic polymer enables stabilization

Hydration water

Water acts as the lubricating element.

U.Raviv, J. Klein, Science, 297, 5586 (2002)

W. Briscoe, J. Klein et al., Nature, 444, 191-194 (2006)



How does it work?

A5

AqueousJoint's surface action



AqueousJoint protecting cartilage surfaces



Hydration water surrounding charged elements of AqueousJoint

Water molecules are the actual lubricating elements.

~ +0.35e





